348 related articles for article (PubMed ID: 21615302)
21. Osteopontin levels in patients with papillary thyroid cancer according to the presence of Hashimoto's thyroiditis.
Park SH; Park CS; Kim YI; Nam-Goong IS; Kim YS; Lee JC; Choi JI; Park JW; Kim ES
Asian Pac J Cancer Prev; 2015; 16(6):2447-51. PubMed ID: 25824779
[TBL] [Abstract][Full Text] [Related]
22. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
23. [Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor].
Delektorskaia VV; Smirnova EA; Ponomareva MV; Pavlova TV; Pavlov IA
Arkh Patol; 2010; 72(4):3-6. PubMed ID: 21086628
[TBL] [Abstract][Full Text] [Related]
24. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
25. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
Hao Y; Jin C; Wang J
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
[TBL] [Abstract][Full Text] [Related]
26. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
30. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target.
Magro G; Cataldo I; Amico P; Torrisi A; Vecchio GM; Parenti R; Asioli S; Recupero D; D'Agata V; Mucignat MT; Perris R
Thyroid; 2011 Mar; 21(3):267-77. PubMed ID: 21323588
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
32. Mucin 15 is expressed in human placenta and suppresses invasion of trophoblast-like cells in vitro.
Shyu MK; Lin MC; Shih JC; Lee CN; Huang J; Liao CH; Huang IF; Chen HY; Huang MC; Hsieh FJ
Hum Reprod; 2007 Oct; 22(10):2723-32. PubMed ID: 17720698
[TBL] [Abstract][Full Text] [Related]
33. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.
Lan X; Sun W; Zhang P; He L; Dong W; Wang Z; Liu S; Zhang H
Tumour Biol; 2016 May; 37(5):6117-23. PubMed ID: 26611646
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
36. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
37. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
38. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
[TBL] [Abstract][Full Text] [Related]
39. [Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer].
Hucz J; Kowalska M; Jarzab M; Wiench M
Endokrynol Pol; 2006; 57 Suppl A():18-25. PubMed ID: 17091452
[TBL] [Abstract][Full Text] [Related]
40. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
